{"id":746085,"date":"2019-02-11T17:02:00","date_gmt":"2019-02-11T17:02:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/"},"modified":"2025-05-12T08:58:23","modified_gmt":"2025-05-12T12:58:23","slug":"merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/","title":{"rendered":"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU"},"content":{"rendered":"<p class=\"bwalignc\">       First-Time Data from Pivotal Phase 3 KEYNOTE-426 Trial Showing        KEYTRUDA <sup> \u00ae <\/sup>  (pembrolizumab) in Combination with        Inlyta <sup> \u00ae <\/sup>  (axitinib) Significantly Improved OS,        PFS and ORR Compared to Sunitinib Monotherapy in First-Line Treatment of        Advanced Renal Cell Carcinoma     <\/p>\n<p class=\"bwalignc\">       Three New KEYTRUDA Combination Datasets from the Largest Study of        Anti-PD-1 Therapy in Metastatic Prostate Cancer (KEYNOTE-365)     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that new combination and monotherapy data from the<br \/>\n      company\u2019s broad immuno-oncology research program in genitourinary<br \/>\n      cancers \u2013 renal, prostate and bladder \u2212 will be presented at the 2019<br \/>\n      Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February<br \/>\n      14-16. Survival data from the pivotal Phase 3 KEYNOTE-426 trial with<br \/>\n      KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta<br \/>\n      (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of<br \/>\n      advanced or metastatic renal cell carcinoma (RCC) will be presented for<br \/>\n      the first-time (Abstract #543). In October 2018, Merck announced that<br \/>\n      KEYNOTE-426 met both primary endpoints of overall survival (OS) and<br \/>\n      progression-free survival (PFS), and the key secondary endpoint of<br \/>\n      objective response rate (ORR). Data released today from the first<br \/>\n      interim analysis showed KEYTRUDA in combination with axitinib, when<br \/>\n      compared to sunitinib, significantly improved OS, reducing the risk of<br \/>\n      death by nearly half, (HR 0.53 [95% CI 0.38-0.74]; P=0.0001), as well as<br \/>\n      PFS (HR 0.69 [95% CI 0.57-0.84]; P=0.0001) and ORR (59.3% vs. 35.7%;<br \/>\n      P=0.0001). Results across OS, PFS and ORR were consistent across all<br \/>\n      IMDC risk groups and regardless of PD-L1 expression. Treatment-related<br \/>\n      adverse events were grade 3-5 in 62.9 percent of patients in the<br \/>\n      KEYTRUDA and axitinib arm vs 58.1 percent in the sunitinib arm and led<br \/>\n      to regimen discontinuation in 6.3 percent vs 10.1 percent of patients in<br \/>\n      those arms, respectively. Full results from KEYNOTE-426 will be<br \/>\n      presented at the meeting.\n    <\/p>\n<p>\n      \u201cMerck is pursuing a broad clinical program in advanced cancers of the<br \/>\n      kidney, prostate and bladder with the goal of advancing new treatment<br \/>\n      options for patients afflicted by historically difficult to treat<br \/>\n      malignancies,\u201d said Dr. Roger M. Perlmutter, president, Merck Research<br \/>\n      Laboratories. \u201cThe improvement in survival achieved with KEYTRUDA in<br \/>\n      combination with axitinib for the first-line treatment of advanced renal<br \/>\n      cell carcinoma, which will be described in detail at the ASCO GU<br \/>\n      meeting, underscores this commitment.\u201d\n    <\/p>\n<p>\n      More than 20 abstracts across Merck\u2019s oncology portfolio \u2013 across RCC,<br \/>\n      prostate cancer, non-muscle invasive bladder cancer (NMIBC) and<br \/>\n      urothelial carcinoma \u2013 have been accepted for presentation. Select data<br \/>\n      highlights at ASCO GU include:\n    <\/p>\n<p>\n      Renal Cell Carcinoma\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Abstract #543 Oral Presentation: Pembrolizumab (pembro) plus axitinib<br \/>\n        (axi) versus sunitinib as first-line therapy for locally advanced or<br \/>\n        metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.<br \/>\n        T. Powles. Saturday, Feb. 16. 2:00 p.m.-3:30 p.m. PST.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Abstract #546 Oral Presentation: First-line pembrolizumab (pembro)<br \/>\n        monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC):<br \/>\n        Results from KEYNOTE-427 cohort B. D. McDermott. Saturday, Feb. 16.<br \/>\n        2:00 p.m.-3:30 p.m. PST.\n      <\/li>\n<\/ul>\n<p>\n      Prostate Cancer\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Abstract #145 Rapid Abstract Session: KEYNOTE-365 cohort A:<br \/>\n        Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients<br \/>\n        (pts) with metastatic castrate-resistant prostate cancer (mCRPC). E.<br \/>\n        Yu. Thursday, Feb. 14. 4:35 p.m.-5:30 p.m. PST.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Abstract #170 Poster Session: KEYNOTE-365 cohort B: Pembrolizumab<br \/>\n        (pembro) plus docetaxel and prednisone in abiraterone (abi) or<br \/>\n        enzalutamide (enza)-pretreated patients (pts) with metastatic castrate<br \/>\n        resistant prostate cancer (mCRPC). C. Massard. Thursday, Feb. 14.<br \/>\n        11:30 a.m.-1:00&nbsp;p.m. and 5:30 p.m.-6:30&nbsp;p.m. PST.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Abstract #171 Poster Session: KEYNOTE-365 cohort C: Pembrolizumab<br \/>\n        (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated<br \/>\n        patients (pts) with metastatic castrate resistant prostate cancer<br \/>\n        (mCRPC). P. Fong. Thursday, Feb. 14. 11:30 a.m.-1:00&nbsp;p.m. and<br \/>\n        5:30&nbsp;p.m.-6:30&nbsp;p.m. PST.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Abstract #216 Poster Session: Pembrolizumab for metastatic<br \/>\n        castration-resistant prostate cancer (mCRPC) previously treated with<br \/>\n        docetaxel: Updated analysis of KEYNOTE-199. E. Antonarakis. Thursday,<br \/>\n        Feb. 14. 11:30 a.m.-1:00&nbsp;p.m. and 5:30&nbsp;p.m.-6:30&nbsp;p.m. PST.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Abstract #TPS340 Poster Session: PROPEL: A randomized, phase III trial<br \/>\n        evaluating the efficacy and safety of olaparib combined with<br \/>\n        abiraterone as first-line therapy in patients with metastatic<br \/>\n        castration-resistant prostate cancer (mCRPC). N. Clarke. Thursday,<br \/>\n        Feb. 14. 11:30 a.m.-1:00&nbsp;p.m. and 5:30&nbsp;p.m.-6:30&nbsp;p.m. PST.\n      <\/li>\n<\/ul>\n<p>\n      Bladder Cancer\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Abstract #350 Welcome and General Session: KEYNOTE-057: Phase II trial<br \/>\n        of Pembrolizumab (pembro) for patients (pts) with high-risk (HR)<br \/>\n        nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus<br \/>\n        calmette-gu\u00e9rin (BCG). A. Balar. Friday, Feb. 15. 7:55 a.m.-9:25 a.m.<br \/>\n        PST.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Abstract #433 Poster Session: Association between stromal\/TGF-\u03b2\/EMT<br \/>\n        gene expression signature and response to pembrolizumab monotherapy in<br \/>\n        cisplatin-ineligible patients with locally advanced (unresectable) or<br \/>\n        metastatic urothelial carcinoma. P. Grivas. Friday, Feb. 15. 12:15<br \/>\n        p.m.-1:45 p.m. and 5:15 p.m.- 6:15&nbsp;p.m. PST.\n      <\/li>\n<\/ul>\n<p>\n      For more information, including a complete list of abstract titles and<br \/>\n      presentation dates and times for Merck\u2019s oncology portfolio, please<br \/>\n      visit the ASCO GU website at <a href=\"https:\/\/meetings.asco.org\/gu\" rel=\"nofollow\">https:\/\/meetings.asco.org\/gu<\/a>.\n    <\/p>\n<p>\n      <b>About KEYNOTE-426<\/b>\n    <\/p>\n<p>\n      KEYNOTE-426 is a randomized, double-arm, Phase 3 trial<br \/>\n      (ClinicalTrials.gov, NCT02853331) evaluating the safety and efficacy of<br \/>\n      KEYTRUDA in combination with axitinib as first-line treatment for<br \/>\n      advanced or metastatic RCC compared to sunitinib. The dual primary<br \/>\n      endpoints of the study were OS and PFS, and the key secondary endpoint<br \/>\n      was ORR. Additional secondary endpoints were disease control rate (DCR),<br \/>\n      number of participants who experienced or discontinued the study due to<br \/>\n      an adverse event (AE), duration of response (DOR), PFS at 12, 18 and 24<br \/>\n      months and OS at 12, 18 and 24 months. In the trial, 861 patients were<br \/>\n      randomly assigned to receive KEYTRUDA 200 mg intravenously every three<br \/>\n      weeks plus axitinib 5 mg orally twice daily for up to 24 months, or<br \/>\n      sunitinib 50 mg orally once daily for four weeks followed by no<br \/>\n      treatment for two weeks, continuously.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection,<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 900 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK<br \/>\n      genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with carboplatin and either paclitaxel or<br \/>\n      nab-paclitaxel, is indicated for the first-line treatment of patients<br \/>\n      with metastatic squamous NSCLC.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic NSCLC whose tumors have high PD-L1<br \/>\n      expression [tumor proportion score (TPS) \u226550%] as determined by an<br \/>\n      FDA-approved test, with no EGFR or ALK<i> <\/i>genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the treatment of patients<br \/>\n      with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for the chemotherapy agents<br \/>\n      administered in combination with KEYTRUDA, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after 3 or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression. In pediatric<br \/>\n      patients with PMBCL, KEYTRUDA is administered at a dose of 2 mg\/kg (up<br \/>\n      to a maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [combined positive score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [combined positive score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is a fixed dose of<br \/>\n      200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Hepatocellular Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with hepatocellular<br \/>\n      carcinoma (HCC) who have been previously treated with sorafenib. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Merkel Cell Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with recurrent locally advanced or metastatic Merkel cell carcinoma.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA in adults is 200 mg administered as an intravenous infusion<br \/>\n      over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. The recommended dose of KEYTRUDA in pediatric patients is 2<br \/>\n      mg\/kg (up to a maximum of 200 mg), administered as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 3.4% (94\/2799) of patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%),<br \/>\n      and occurred more frequently in patients with a history of prior<br \/>\n      thoracic radiation (6.9%) compared to those without (2.9%). Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%<br \/>\n      (48\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of<br \/>\n      colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%<br \/>\n      (19\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function.<br \/>\n      Administer corticosteroids for Grade 2 or greater hepatitis and, based<br \/>\n      on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes<br \/>\n      mellitus. Hypophysitis occurred in 0.6% (17\/2799) of patients, including<br \/>\n      Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC, occurring in 15% (28\/192) of patients. Hyperthyroidism occurred<br \/>\n      in 3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%),<br \/>\n      and thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade<br \/>\n      2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and<br \/>\n      withhold KEYTRUDA and administer antihyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%<br \/>\n      (9\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of<br \/>\n      patients receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA and<br \/>\n      may also occur after discontinuation of treatment. For suspected<br \/>\n      immune-mediated adverse reactions, ensure adequate evaluation to confirm<br \/>\n      etiology or exclude other causes. Based on the severity of the adverse<br \/>\n      reaction, withhold KEYTRUDA and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials and postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 0.2% (6\/2799) of patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b>\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of<br \/>\n      23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6<br \/>\n      developed graft-versus-host disease (GVHD) (1 fatal case) and 2<br \/>\n      developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute<br \/>\n      GVHD after allogeneic HSCT have also been reported in patients with<br \/>\n      lymphoma who received a PD-1 receptor\u2013blocking antibody before<br \/>\n      transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD) has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients With Multiple Myeloma<\/b>\n    <\/p>\n<p>\n      In trials in patients with multiple myeloma, the addition of KEYTRUDA to<br \/>\n      a thalidomide analogue plus dexamethasone resulted in increased<br \/>\n      mortality. Treatment of these patients with a PD-1 or PD-L1 blocking<br \/>\n      antibody in this combination is not recommended outside of controlled<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b>\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. Advise women of this potential risk.<br \/>\n      In females of reproductive potential, verify pregnancy status prior to<br \/>\n      initiating KEYTRUDA and advise them to use effective contraception<br \/>\n      during treatment and for 4 months after the last dose.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      permanent discontinuation in more than one patient were colitis (1.4%),<br \/>\n      autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy<br \/>\n      (0.4%), and cardiac failure (0.4%). The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and<br \/>\n      nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and<br \/>\n      either paclitaxel or nab-paclitaxel in metastatic squamous NSCLC,<br \/>\n      KEYTRUDA was discontinued due to adverse reactions in 15% of 101<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were febrile neutropenia, pneumonia, and urinary<br \/>\n      tract infection. Adverse reactions observed in KEYNOTE-407 were similar<br \/>\n      to those observed in KEYNOTE-189 with the exception that increased<br \/>\n      incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs<br \/>\n      25%) were observed in the KEYTRUDA and chemotherapy arm compared to the<br \/>\n      placebo and chemotherapy arm in KEYNOTE-407.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC who<br \/>\n      received KEYTRUDA as a monotherapy, with the exception of increased<br \/>\n      incidences of facial edema and new or worsening hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1<br \/>\n      from septic shock. The most common adverse reactions (\u226520%) were fatigue<br \/>\n      (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea<br \/>\n      (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with gastric cancer were similar<br \/>\n      to those occurring in patients with melanoma or NSCLC who received<br \/>\n      KEYTRUDA as a monotherapy.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with HCC were generally similar<br \/>\n      to those in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy, with the exception of increased incidences of ascites (8%<br \/>\n      Grades 3-4) and immune-mediated hepatitis (2.9%). Laboratory<br \/>\n      abnormalities (Grades 3-4) that occurred at a higher incidence were<br \/>\n      elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).\n    <\/p>\n<p>\n      Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse<br \/>\n      reactions occurring in patients with MCC were generally similar to those<br \/>\n      occurring in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a<br \/>\n      higher incidence were elevated AST (11%) and hyperglycemia (19%).\n    <\/p>\n<p>\n      <b>Lactation<\/b>\n    <\/p>\n<p>\n      Because of the potential for serious adverse reactions in breastfed<br \/>\n      children, advise women not to breastfeed during treatment and for 4<br \/>\n      months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b>\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a trial, in 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with various cancers,<br \/>\n      including unapproved usages, were administered KEYTRUDA 2 mg\/kg every 3<br \/>\n      weeks. Patients received KEYTRUDA for a median of 3 doses (range 1\u201317<br \/>\n      doses), with 34 patients (85%) receiving 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults;<br \/>\n      adverse reactions that occurred at a higher rate (\u226515% difference) in<br \/>\n      these patients when compared to adults under 65 years of age were<br \/>\n      fatigue (45%), vomiting (38%), abdominal pain (28%), increased<br \/>\n      transaminases (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a first-in-class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as BRCA mutations, to preferentially kill cancer<br \/>\n      cells. Inhibition of PARP with LYNPARZA leads to the trapping of PARP<br \/>\n      bound to DNA single-strand breaks, stalling of replication forks, their<br \/>\n      collapse and the generation of DNA double-strand breaks and cancer cell<br \/>\n      death. LYNPARZA is being tested in a range of tumor types with defects<br \/>\n      and dependencies in the DDR.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      understand how it may affect multiple PARP-dependent tumors as a<br \/>\n      monotherapy and in combination across multiple cancer types.\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION<\/b>\n    <\/p>\n<p>\n      <b>CONTRAINDICATIONS<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML):<\/b><br \/>\n      Occurred in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the<br \/>\n      majority of events had a fatal outcome. The duration of therapy in<br \/>\n      patients who developed secondary MDS\/AML varied from &lt;6 months to &gt;2<br \/>\n      years. All of these patients had previous chemotherapy with platinum<br \/>\n      agents and\/or other DNA-damaging agents, including radiotherapy, and<br \/>\n      some also had a history of more than one primary malignancy or of bone<br \/>\n      marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity:<\/b> Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014First-Line Maintenance BRCAm Advanced Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226510% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting<\/b><br \/>\n      for <b>SOLO-1<\/b> were: nausea (77%), fatigue (67%), abdominal pain<br \/>\n      (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%),<br \/>\n      upper respiratory tract infection\/influenza\/ nasopharyngitis\/bronchitis<br \/>\n      (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%),<br \/>\n      neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI<br \/>\n      (13%), thrombocytopenia (11%), and stomatitis (11%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting<\/b><br \/>\n      for <b>SOLO-1<\/b> were: decrease in hemoglobin (87%), increase in mean<br \/>\n      corpuscular volume (87%), decrease in leukocytes (70%), decrease in<br \/>\n      lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease<br \/>\n      in platelets (35%), and increase in serum creatinine (34%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting<\/b> for <b>SOLO-2<\/b><br \/>\n      were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%),<br \/>\n      vomiting (37%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia (30%),<br \/>\n      dysgeusia (27%), headache (26%), decreased appetite (22%), and<br \/>\n      stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19:<\/b> nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), decreased appetite<br \/>\n      (21%), and dyspepsia (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19)<\/b> were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced gBRCAm ovarian cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced gBRCAm ovarian cancer after<br \/>\n      3 or more lines of chemotherapy<\/b> (pooled from 6 studies) were:<br \/>\n      fatigue\/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%),<br \/>\n      diarrhea (31%), nasopharyngitis\/upper respiratory tract infection (URI)<br \/>\n      (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and<br \/>\n      arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced gBRCAm ovarian cancer<\/b><br \/>\n      (pooled from 6 studies) were: decrease in hemoglobin (90%), mean<br \/>\n      corpuscular volume elevation (57%), decrease in lymphocytes (56%),<br \/>\n      increase in serum creatinine (30%), decrease in platelets (30%), and<br \/>\n      decrease in absolute neutrophil count (25%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014gBRCAm, HER2-negative metastatic breast cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b><br \/>\n      were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%),<br \/>\n      vomiting (30%), neutropenia (27%), respiratory tract infection (27%),<br \/>\n      leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in &gt;25% of patients in <b>OlympiAD<\/b><br \/>\n      were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents:<\/b> Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors:<\/b> Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers:<\/b> Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Lactation:<\/b> No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use:<\/b> The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment:<\/b> No adjustment to the starting dose is<br \/>\n      required in patients with mild or moderate hepatic impairment<br \/>\n      (Child-Pugh classification A and B). There are no data in patients with<br \/>\n      severe hepatic impairment (Child-Pugh classification C).\n    <\/p>\n<p>\n      <b>Renal Impairment:<\/b> No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min) but patients<br \/>\n      should be monitored closely for toxicity. In patients with moderate<br \/>\n      renal impairment (CLcr=31-50 mL\/min), reduce the dose to 200 mg twice<br \/>\n      daily. There are no data in patients with severe renal impairment or<br \/>\n      end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>INDICATIONS<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      <b>First-Line Maintenance BRCAm Advanced Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with deleterious or<br \/>\n      suspected deleterious germline or somatic BRCA-mutated (gBRCAm or<br \/>\n      sBRCAm) advanced epithelial ovarian, fallopian tube or primary<br \/>\n      peritoneal cancer who are in complete or partial response to first-line<br \/>\n      platinum-based chemotherapy. Select patients with gBRCAm advanced<br \/>\n      epithelial ovarian, fallopian tube or primary peritoneal cancer for<br \/>\n      therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      <b>Advanced gBRCAm ovarian cancer<\/b>\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who<br \/>\n      have been treated with 3 or more prior lines of chemotherapy. Select<br \/>\n      patients for therapy based on an FDA-approved companion diagnostic for<br \/>\n      LYNPARZA.\n    <\/p>\n<p>\n      <b>gBRCAm, HER2-negative metastatic breast cancer<\/b>\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious gBRCAm, human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have been treated with chemotherapy in the neoadjuvant,<br \/>\n      adjuvant or metastatic setting. Patients with hormone receptor<br \/>\n      (HR)-positive breast cancer should have been treated with a prior<br \/>\n      endocrine therapy or be considered inappropriate for endocrine therapy.<br \/>\n      Select patients for therapy based on an FDA-approved companion<br \/>\n      diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      Please click <a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\">here<\/a><br \/>\n      for complete Prescribing Information, including Patient Information<br \/>\n      (Medication Guide).\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele<br \/>(267) 305-3558<br \/>Elizabeth H. Sell<br \/>(267)        305-3877     <\/p>\n<p>       Investors:<br \/>Teri Loxam<br \/>(908) 740-1986<br \/>Peter Dannenbaum<br \/>(908)        740-1037     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from the company\u2019s broad immuno-oncology research program in genitourinary cancers \u2013 renal, prostate and bladder \u2212 will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16. Survival data from the pivotal Phase 3 KEYNOTE-426 trial with KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced or metastatic renal cell carcinoma (RCC) will be presented for the first-time (Abstract #543). In October 2018, Merck announced that KEYNOTE-426 met both primary endpoints of overall survival (OS) and progression-free survival (PFS), and the key secondary endpoint of objective response rate (ORR). Data released today from the first interim analysis showed KEYTRUDA in combination with axitinib, when compared to sunitinib, significantly<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-746085","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from the company\u2019s broad immuno-oncology research program in genitourinary cancers \u2013 renal, prostate and bladder \u2212 will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16. Survival data from the pivotal Phase 3 KEYNOTE-426 trial with KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced or metastatic renal cell carcinoma (RCC) will be presented for the first-time (Abstract #543). In October 2018, Merck announced that KEYNOTE-426 met both primary endpoints of overall survival (OS) and progression-free survival (PFS), and the key secondary endpoint of objective response rate (ORR). Data released today from the first interim analysis showed KEYTRUDA in combination with axitinib, when compared to sunitinib, significantly\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"32 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/\",\"name\":\"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-02-11T17:02:00+00:00\",\"dateModified\":\"2025-05-12T12:58:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/","og_locale":"en_US","og_type":"article","og_title":"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from the company\u2019s broad immuno-oncology research program in genitourinary cancers \u2013 renal, prostate and bladder \u2212 will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16. Survival data from the pivotal Phase 3 KEYNOTE-426 trial with KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced or metastatic renal cell carcinoma (RCC) will be presented for the first-time (Abstract #543). In October 2018, Merck announced that KEYNOTE-426 met both primary endpoints of overall survival (OS) and progression-free survival (PFS), and the key secondary endpoint of objective response rate (ORR). Data released today from the first interim analysis showed KEYTRUDA in combination with axitinib, when compared to sunitinib, significantly","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:23+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"32 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/","name":"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-02-11T17:02:00+00:00","dateModified":"2025-05-12T12:58:23+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"21a40f75-0243-46fd-a86a-0c359a7737d4","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Highlights-Breadth-of-Immuno-Oncology-Research-Program-in-Genitourinary-Cancers-at-ASCO-GU-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746085\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746085"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}